These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21595268)

  • 1. [Effects of incretin on cardiovascular disease and risk factors].
    Kodama K; Node K
    Nihon Rinsho; 2011 May; 69(5):836-41. PubMed ID: 21595268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.
    Mannucci E; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Nov; 18(9):639-45. PubMed ID: 18849155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies.
    Chilton R; Wyatt J; Nandish S; Oliveros R; Lujan M
    Am J Med; 2011 Jan; 124(1 Suppl):S35-53. PubMed ID: 21194579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of glucagon-like peptide-1 on endothelial function.
    Sjöholm A
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():19-25. PubMed ID: 19878258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Glucagon-like peptide-1 analogues and cardiovascular risk factors: evidence from clinical trials].
    Mannucci E
    G Ital Cardiol (Rome); 2010 Dec; 11(12 Suppl 2):26S-29S. PubMed ID: 21361053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
    Unger J
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.
    Rizzo M; Rizvi AA; Spinas GA; Rini GB; Berneis K
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1495-503. PubMed ID: 19758106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Glucagon like peptide-1 and the cardiovascular system: pathophysiological mechanisms].
    Avogaro A
    G Ital Cardiol (Rome); 2010 Dec; 11(12 Suppl 2):18S-25S. PubMed ID: 21361052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
    Nauck MA
    Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond insulin replacement: addressing the additional needs of the diabetes patient.
    Dailey G
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():83-97. PubMed ID: 18577160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Glucagon-like peptide-1: pleiotropic effects on the cardiovascular system].
    Avogaro A
    G Ital Cardiol (Rome); 2008 Nov; 9(11):753-8. PubMed ID: 19058666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus.
    Blonde L
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S4-11. PubMed ID: 19952303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin based therapies for type 2 diabetes mellitus.
    Ghosh S; Collier A; Elhadd T; Malik I
    J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Protective effects of incretin on atherosclerosis].
    Mita T; Watada H
    Nihon Rinsho; 2011 May; 69(5):831-5. PubMed ID: 21595267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin-based therapy and type 2 diabetes.
    Hare KJ; Knop FK
    Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?
    Giugliano D; Standl E; Vilsbøll T; Betteridge J; Bonadonna R; Campbell IW; Schernthaner GH; Staels B; Trichopoulou A; Farinaro E
    Acta Diabetol; 2009 Sep; 46(3):173-81. PubMed ID: 19543848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.